New research unlocks medical potential of jellyfish biomaterial


This article has been reviewed in accordance with Science X’s editorial processes and policies. The editors have highlighted the following attributes while ensuring the authenticity of the content:

fact confirmed

trusted sources

proofread


Graphical abstraction. credit: Today’s Materials Bio (2023). DOI: 10.1016/j.mtbio.2023.100786

× close


Graphical abstraction. credit: Today’s Materials Bio (2023). DOI: 10.1016/j.mtbio.2023.100786

New research by the National Physical Laboratory (NPL) and British biotech company Geragen reveals that jellyfish collagen could form the basis of a range of new medical applications and support new biological research. I did.

Jellagen partnered with NPL to help develop jellyfish collagen into high-value, high-spec biomaterial products for use in healthcare.The research results were published in a magazine Today’s Materials Biocontains detailed evidence on the properties of jellyfish collagen-based biomaterials that underpin a wide range of products.

This biomaterial has been shown to support the development of a variety of human cells, including stem cells, cancer cells, and primary cells, and has also been shown to support the development of a variety of human cells, including stem cells, cancer cells, and primary cells, and to support specialized biological applications such as simultaneous neuron firing, stem cell differentiation, and cancer spheroid formation. It also supports scientific functions.

The partnership, which began through the UK’s innovation agency Innovate UKs Analysis for Innovators Program, will help explain the mechanical behavior of collagen and identify optimal conditions for effectively manufacturing collagen-based products. , provided a clearer path for ongoing product development and research. Moreover.

Most cells in the human body require physical support to reproduce, communicate, and form tissues and organs. A network of proteins called the extracellular matrix (or ECM) provides this support by acting as a scaffold to house cells, allowing the development of model tissues that more effectively mimic tissues in the body.

The importance of these matrices in tissue development makes this scaffold functional for use in a variety of medical applications, from hydrogels to promote tissue regeneration and tumor-mimicking organoids to 3D cell factories for bioengineering. The search for similar materials is underway.

In response to this research, British biotechnology company Jellagen Ltd. is based on the jellyfish collagen ECM matrix, which has existed for more than 500 million years and has been consistently replicated in other life forms for millions of years. We have developed an innovative biomaterial that

The jellyfish matrix is ​​similar to multiple matrix types found in a variety of animals, from dinosaurs to humans. Although it is older than all other matrix types, it does not itself belong to any one type.Therefore, it was named extracellular matrix [ECM] Type 0 (“zero”) – that is, the first precursor to all other matrices that follow.

The study results illustrate extensive evidence regarding the performance properties of biomaterials that underpin a versatile pipeline of products commercialized under the generic name JellaGel.

“By collaborating with NPL, Jellagen will have access to cutting-edge expertise in the analysis and characterization of collagen biomaterials,” said Andrew Mearns Spragg, Managing Director and CSO of Jellagen. “This collaboration provides us with valuable access to important resources to support our research.” As a pioneer of all matrices, he provided key insights in scientifically establishing the concept of ECM type 0 (zero). ”

“We highly recommend NPL to other biotech companies seeking fundamental understanding of how their materials behave at biological interfaces and look forward to building on this partnership in the future. I’m looking forward to doing that.”

Max Ryadnov, NPL Bioinstrumentation Researcher, said: “This was an exciting collaboration and we also learned a lot from biomaterials. There is great interest in extracellular matrices in industry and medicine. Despite this, and despite the fact that there are many matrices in development, very few reach the final product stage, let alone be manufactured at scale.”

“We are very pleased to have played a key role in the development of this pioneering and versatile product.”

For more information:
Nilofar Faruqui et al, Extracellular Matrix Type 0: From an Ancient Collagen Lineage to a Versatile Product Pipeline – JellaGel, Today’s Materials Bio (2023). DOI: 10.1016/j.mtbio.2023.100786



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *